Laplace Interventional, a Minnesota-based medical device company developing a transcatheter tricuspid valve technology, announced that it has completed its Series C financing led by a non-disclosed global strategic investor along with investments from Aphelion Capital, Engage Venture Partners, Unorthodox Ventures, JWC Venture and Features Capital. The company also announced the addition of Ned Scheetz, Founding Managing Partner at Aphelion Capital, to its Board of Directors.
Laplace Interventional’s device is expected to improve the quality of life of patients worldwide diagnosed with Tricuspid Regurgitation (TR). Laplace Interventional is developing a prosthetic valve that is delivered through a minimally invasive procedure that does not require open-heart surgery, thereby reducing future complications in patients.
Laplace enrolled 22 patients in the United States largely as part of their US EFS Study (and 25 globally) with encouraging results.
KEY QUOTES:
“So far we have treated three patients in the Laplace EFS and all were discharged home within 1-2 days and are doing well. This was our first experience with a dedicated transcatheter tricuspid valve replacement platform and we are highly impressed with the intuitive deployment, imaging requirements, and overall ease of use of the Laplace system in a variety of challenging anatomies,” said
- Dr. Brandon Jones, Interventional Cardiologist and Medical Director of Structural Heart at Providence St. Vincent Medical Center, Portland, Oregon
“This round of financing marks a significant milestone for the company and further validates our progress over the past few years. We are grateful to our patients, physicians as well as new and existing investors for their continued support and look forward to working towards starting a pivotal trial.” Laplace Interventional plans to use the funds raised from this round towards completing their feasibility study (US EFS and OUS) and work towards a pivotal study.
- Ramji Iyer, PhD, Founder and CEO of Laplace Interventional
“Aphelion Cardeation, a venture fund formed to invest in innovative health care products, services and technologies that align with the mission of the American Heart Association, is proud to participate in this round of financing. We are inspired by Laplace’s innovative solution for TR and its potential to transform care for millions of patients worldwide.”
- Ned Scheetz with Aphelion Capital
